Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence.

Fagerström Consulting, Jordkull 3670, 26878 Kagerod, Sweden.
Nicotine & Tobacco Research (Impact Factor: 2.81). 01/2012; 14(1):75-8. DOI: 10.1093/ntr/ntr137
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Presently, electronic cigarettes (e-cigarettes) are studied as though they are a homogeneous category. However, there are several noteworthy differences in the products that fall under this name including potential differences in the efficacy of these products as smoking cessation aids. The current study examined the comparative efficacy of 1st and 2nd generation e-cigarettes in reducing nicotine withdrawal symptoms in a sample of current smokers with little or no experience using e-cigarettes. Twenty-two mildly to moderately nicotine dependent individuals were randomized to a crossover design in which they used 1st and 2nd generation e-cigarettes on separate days with assessment of withdrawal symptoms directly prior to and after product use. A community based sample recruited in the Midwest region of the United States reported a mean age of 28.6 (SD = 12.9), the majority were male (56.5%), Caucasian (91.3%), reported smoking an average of 15.2 (SD = 9.6) tobacco cigarettes per day, and a mean baseline carbon monoxide (CO) level of 18.7 ppm. Symptoms of withdrawal from nicotine were measured via the Mood and Physical Symptoms Scale. Analysis of changes in withdrawal symptoms revealed a significant time by product interaction F(1, 21) = 5.057, p = .036, n2p = .202. Participants experienced a larger reduction in symptoms of nicotine withdrawal after using 2nd generation e-cigarettes as compared with 1st generation e-cigarettes. Second generation e-cigarettes seem to be more effective in reducing symptoms of nicotine withdrawal than 1st generation e-cigarettes. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Addiction 02/2015; DOI:10.1111/add.12870 · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evidence from alcohol self-administration studies suggests that nicotine replacement therapy may influence subjective and behavioral responses to alcohol. However, its effect on alcohol cue-reactivity is unknown. The present study examined the impact of acutely administered nicotine on subjective responses to alcohol-focused pictorial stimuli. In a mixed within/between-subjects design, nondependent smokers (n = 51) and dependent smokers (n = 45) who socially drink were assigned to either a nicotine (4 mg) or placebo lozenge condition following overnight tobacco abstinence. Following lozenge absorption, participants viewed neutral images followed by alcohol-focused pictures. Craving measures for alcohol and tobacco were completed at baseline, following lozenge absorption, following neutral cues, and following alcohol cues. The presentation of alcohol cues increased alcohol-related craving relative to neutral cues, especially among men, but the administration of nicotine did not influence the magnitude of these effects. Nicotine lozenges were found to decrease intentions to smoke and withdrawal-related craving in dependent but not in nondependent smokers. Finally, the presentation of alcohol cues was found to increase intentions to smoke relative to neutral cues across participants regardless of lozenge condition. Findings suggest that although the presentation of alcohol cues can increase alcohol- and tobacco-related cravings in smokers, such effects do not appear to be affected by acute nicotine administration. (PsycINFO Database Record (c) 2015 APA, all rights reserved).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung: Die chronisch obstruktive Lungenerkrankung (chronic obstructive pulmonary disease, abgekürzt: COPD) ist eine der weltweit führenden Todesursachen. Das Rauchen ist die mit Abstand häufigste Ursache der COPD. Der Verzicht auf Tabakrauchen ist deswegen die effektivste Einzelmaßnahme und zentraler Aspekt der Prävention der COPD. Zum Thema COPD sind mehrere Leitlinien publiziert, die bereits zu Prävention, Diagnostik, Therapie und Rehabilitation Stellung nehmen. Um eine Standardisierung und Etablierung der Tabakentwöhnung flächendeckend in Deutschland zu gewährleisten, wurde im Jahr 2008 aufgrund der Komplexität des Themas eine eigene Leitlinie zur Tabakentwöhnung bei COPD entwickelt. Die vorliegende Fassung ist ein Update dieser Leitlinie Tabakentwöhnung bei COPD unter Berücksichtigung aktueller Erkenntnisse und Forschungsergebnisse. Aufgabe der S3-Leitlinie ist es, die Tabakentwöhnung bei Patienten mit COPD als zentralen Aspekt der Therapie ausführlich und praxisnah abzubilden. Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. Cigarette smoking is the main cause of COPD. Quitting smoking is thus the most effective treatment strategy and central in COPD prevention. A number of guidelines on prevention, diagnosis, therapy and rehabilitation of COPD have been published. To help implementing and standardizing smoking cessation in COPD a guideline was published 2008 in Germany focusing on this complex issue. The present guideline is an update of the 2008 guideline and has a high grade of evidence (S3 according to the AWMF; Arbeitsgemeinschaft wissenschaftlicher medizinischer Fachgesellschaften). The guideline gives comprehensive and practical information on how to integrate smoking cessation as an central part of COPD therapy.
    Pneumologie 01/2014; 68(04):237‐ 258.


Available from
Dec 11, 2014